Kiniksa 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 


«12345678»
  • ||||||||||  Arcalyst (rilonacept) / Regeneron, Kiniksa
    [VIRTUAL] CORTICOSTEROID TAPERING AND DISCONTINUATION IN A PHASE 2 STUDY OF RILONACEPT IN RECURRENT PERICARDITIS (eAbstract Virtual Hall) -  Dec 22, 2019 - Abstract #ACC2020ACC_5516;    
    In this Phase 2 study, rilonacept treatment reduced pain and CRP and enabled tapering and discontinuation of CS in RP of idiopathic or PPS etiology without inducing disease recurrence. This CS-sparing effect of rilonacept has the potential to decrease or even obviate CS use in RP and could represent an important therapeutic opportunity for targeted treatment of this serious and debilitating disease.
  • ||||||||||  Arcalyst (rilonacept) / Regeneron
    NOVEL NOD2 MUTATION CAUSING NOD2 ASSOCIATED AUTOINFLAMMATORY DISEASE (NAID) (Monitor 5) -  Nov 9, 2019 - Abstract #ACAAI2019ACAAI_776;    
    She is currently on treatment with Rilonacept, with symptom control...Loss of structure or function variants of NOD2 are known to be pathogenic, causing several diseases. This case reinforces the need to functionally evaluate all mutations found in patients with unusual clinical pictures.
  • ||||||||||  Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J
    Biomarker, PK/PD data, Journal:  Pharmacodynamic biomarkers and differential effects of TNF- and GM-CSF-targeting biologics in rheumatoid arthritis. (Pubmed Central) -  Sep 6, 2019   
    Our results revealed golimumab- and mavrilimumab-specific pharmacodynamic biomarkers, and demonstrated differential biomarker-treatment relationships in anti-TNF-IR and DMARD-IR patients, respectively. Early IL-6 change after anti-TNF antibody treatment may be a potential predictive biomarker for selection of different treatment regimens in anti-TNF-IR patients.
  • ||||||||||  Ilaris (canakinumab) / Novartis
    Clinical, Journal:  Canakinumab treatment in renal transplant recipients with familial Mediterranean fever. (Pubmed Central) -  Aug 15, 2019   
    We report here the efficacy and safety of canakinumab in three renal transplant recipients who achieved a complete clinical response with elimination of attacks and normalization of serum C-reactive protein (CRP) levels without significant side effects. This highlights the advantage of use of this drug in this setting, which has a better tolerability compared to anakinra.
  • ||||||||||  mavrilimumab (KPL-301) / Kiniksa
    Journal:  Mavrilimumab: a unique insight and update on the current status in the treatment of rheumatoid arthritis. (Pubmed Central) -  Jul 13, 2019   
    Expert opinion: According to the promising results from phase I-II RCTs, mavrilimumab could be considered as an additional therapeutic option for RA patients multi-resistant to the available targeted drugs. However, the optimal dose and the profile of this new drug should be confirmed in phase III RCTs before the marketing.
  • ||||||||||  Kineret (anakinra) / SOBI, Affibody, Arcalyst (rilonacept) / Regeneron, Ilaris (canakinumab) / Novartis
    Journal:  The Future of IL-1 Targeting in Kidney Disease. (Pubmed Central) -  May 17, 2019   
    Additionally, experimental evidence suggests a role of IL-1 in kidney disease and hypertension and targeting IL-1 showed promising results in high cardiovascular risk patients, hemodialysis and renal transplantation patients. We now summarize knowledge on the potential role of IL-1 targeting in patients with kidney disease.
  • ||||||||||  Arcalyst (rilonacept) / Regeneron, Kiniksa
    Trial completion:  Cold Contact Urticaria Treatment With Rilonacept (clinicaltrials.gov) -  Jul 17, 2018   
    P2,  N=20, Completed, 
    Not yet recruiting --> Recruiting Active, not recruiting --> Completed
  • ||||||||||  Arcalyst (rilonacept) / Regeneron, Kiniksa
    Enrollment closed:  Cold Contact Urticaria Treatment With Rilonacept (clinicaltrials.gov) -  Dec 15, 2017   
    P2,  N=20, Active, not recruiting, 
    Phase classification: P=N/A --> P2 Recruiting --> Active, not recruiting
  • ||||||||||  Arcalyst (rilonacept) / Regeneron, Kiniksa
    Biomarker, Trial completion:  IL1-TRAP, Rilonacept, in Systemic Sclerosis (clinicaltrials.gov) -  Dec 5, 2017   
    P1/2,  N=21, Completed, 
    Recruiting --> Active, not recruiting Active, not recruiting --> Completed
  • ||||||||||  Arcalyst (rilonacept) / Regeneron, Kiniksa
    Enrollment open, Trial initiation date, Trial primary completion date:  Rilonacept for Treatment of Autoimmune Neurosensory Hearing Loss (clinicaltrials.gov) -  Sep 13, 2017   
    P,  N=10, Recruiting, 
    Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Jul 2016 --> Feb 2017 | Trial primary completion date: Jun 2017 --> Mar 2018
  • ||||||||||  mavrilimumab (KPL-301) / Kiniksa
    Trial initiation date, Trial termination:  A Long Term Safety Study of Mavrilimumab in Adult Subjects With Rheumatoid Arthritis (clinicaltrials.gov) -  Jun 1, 2017   
    P2,  N=409, Terminated, 
    Not yet recruiting --> Recruiting | Initiation date: Jul 2016 --> Feb 2017 | Trial primary completion date: Jun 2017 --> Mar 2018 Initiation date: Dec 2002 --> Jan 2013 | Completed --> Terminated; The study was terminated after approximately 3 years due to future clinical development plans, including ethical considerations.
  • ||||||||||  Arcalyst (rilonacept) / Regeneron, Kiniksa
    Biomarker, Enrollment closed, Enrollment change:  IL1-TRAP, Rilonacept, in Systemic Sclerosis (clinicaltrials.gov) -  Mar 30, 2017   
    P1/2,  N=19, Active, not recruiting, 
    Initiation date: Dec 2002 --> Jan 2013 | Completed --> Terminated; The study was terminated after approximately 3 years due to future clinical development plans, including ethical considerations. Recruiting --> Active, not recruiting | N=40 --> 19
  • ||||||||||  Arcalyst (rilonacept) / Regeneron, Kiniksa
    Trial primary completion date:  Cold Contact Urticaria Treatment With Rilonacept (clinicaltrials.gov) -  Jan 6, 2017   
    P2,  N=20, Recruiting, 
    Recruiting --> Active, not recruiting | N=40 --> 19 Trial primary completion date: Feb 2017 --> Dec 2017
  • ||||||||||  Arcalyst (rilonacept) / Regeneron, Kiniksa
    Trial completion:  Rilonacept for Deficiency of the Interleukin-1 Receptor Antagonist (DIRA) (clinicaltrials.gov) -  May 3, 2016   
    P2,  N=6, Completed, 
    Trial primary completion date: Feb 2017 --> Dec 2017 Active, not recruiting --> Completed
  • ||||||||||  mavrilimumab (KPL-301) / Kiniksa
    Trial completion, Trial initiation date:  A Long Term Safety Study of Mavrilimumab in Adult Subjects With Rheumatoid Arthritis (clinicaltrials.gov) -  Feb 3, 2016   
    P2,  N=409, Completed, 
    Not yet recruiting --> Completed | N=186 --> 5 | Trial primary completion date: Sep 2018 --> Apr 2016 Active, not recruiting --> Completed | Initiation date: Aug 2012 --> Dec 2002
  • ||||||||||  Arcalyst (rilonacept) / Regeneron, Kiniksa
    Trial primary completion date:  Cold Contact Urticaria Treatment With Rilonacept (clinicaltrials.gov) -  Jan 29, 2016   
    P2,  N=20, Recruiting, 
    Active, not recruiting --> Completed | Initiation date: Aug 2012 --> Dec 2002 Trial primary completion date: Apr 2016 --> Feb 2017
  • ||||||||||  Arcalyst (rilonacept) / Regeneron, Kiniksa
    Trial completion, Trial primary completion date:  Interleukin-1 Trap to Treat Vascular Dysfunction in Chronic Kidney Disease (CKD) (clinicaltrials.gov) -  Sep 17, 2015   
    P4,  N=38, Completed, 
    Trial primary completion date: Apr 2016 --> Feb 2017 Recruiting --> Completed | Trial primary completion date: Dec 2016 --> Dec 2014